Statements (23)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:acquiredBy |
gptkb:Otsuka_Pharmaceutical
|
| gptkbp:acquisitionYear |
2013
|
| gptkbp:collaboratedWith |
gptkb:Janssen_Pharmaceutica
gptkb:AstraZeneca gptkb:Novartis GlaxoSmithKline |
| gptkbp:country |
gptkb:United_Kingdom
|
| gptkbp:focusesOn |
oncology
drug discovery central nervous system disorders |
| gptkbp:foundedIn |
1999
|
| gptkbp:headquartersLocation |
gptkb:Cambridge,_United_Kingdom
|
| https://www.w3.org/2000/01/rdf-schema#label |
Astex Therapeutics
|
| gptkbp:industry |
gptkb:biotechnology
|
| gptkbp:notableProduct |
gptkb:AT7519
gptkb:SGI-110 gptkb:cediranib |
| gptkbp:parentCompany |
gptkb:Otsuka_Pharmaceutical
|
| gptkbp:technology |
fragment-based drug discovery
|
| gptkbp:website |
https://www.astx.com/
|
| gptkbp:bfsParent |
gptkb:Sir_Tom_Blundell
|
| gptkbp:bfsLayer |
5
|